TAAT® Global Alternatives Inc. to File Fiscal Q1 2023 Financials on Monday, April 3, 2023 and Provides General Update
TAAT Global Alternatives Inc. (CSE: TAAT) (OTCQX: TOBAF) has announced the scheduled filing of its Fiscal Q1 2023 financial statements on April 3, 2023. In a significant update, the company has terminated its proposed acquisition of the Break Free™ mobile application from Boksburg Ventures Inc., which was initially announced on March 3, 2023. TAAT® is positioned as a vertically integrated consumer product company generating over CAD $90 million in gross revenue annually, actively expanding its product categories in tobacco and reduced-risk alternatives, hemp, and kratom.
- TAAT generates over CAD $90 million in gross revenue annually.
- The company is strategically expanding product categories.
- Termination of the Break Free™ mobile app acquisition may impact growth plans.
LAS VEGAS and VANCOUVER, British Columbia, March 31, 2023 (GLOBE NEWSWIRE) -- TAAT® GLOBAL ALTERNATIVES INC. (CSE: TAAT) (OTCQX: TOBAF) (FRANKFURT: 2TP) (the “Company” or “TAAT®”) is pleased to announce that its financial statements for its Fiscal Q1 2023 (three-month period ended January 31, 2023) will be filed on Monday, April 3, 2023 and will be available on SEDAR (www.sedar.com).
Additionally, the Company announces that the definitive agreement dated December 14, 2022, as amended March 1, 2023 (the “Agreement”), to acquire the Break Free™ mobile application and associated working capital (the “Proposed Transaction”) from Boksburg Ventures Inc. (“Boksburg”), has been terminated. The Proposed Transaction was previously announced by the Company on March 3, 2023.
On behalf of the Board of Directors of the Company,
TAAT® GLOBAL ALTERNATIVES INC.
“Michael Saxon”
Michael Saxon, CEO and Director
For further information, please contact:
TAAT® Investor Relations
1-833-TAAT-USA (1-833-822-8872)
investor@taatglobal.com
THE CANADIAN SECURITIES EXCHANGE (“CSE”) HAS NOT REVIEWED AND DOES NOT ACCEPT RESPONSIBILITY FOR THE ACCURACY OR ADEQUACY OF THIS RELEASE, NOR HAS OR DOES THE CSE’S REGULATION SERVICES PROVIDER.
About TAAT® Global Alternatives Inc.
TAAT® is a vertically integrated consumer product and distribution company, generating more than CAD
For more information, please visit http://taatglobal.com.
Forward-Looking Statements
This news release contains “forward-looking information” within the meaning of applicable Canadian securities legislation. Often, but not always, forward-looking information and information can be identified by the use of words such as “plans”, “expects” or “does not expect”, “is expected”, “estimates”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur, or be achieved. Forward-looking information in this news release includes statements regarding the anticipated performance of TAAT® in the tobacco industry, in addition to the following: Potential outcomes from the termination of the Agreement as outlined in the body of the press release, anticipated filing of the Company’s Fiscal Q1 2023 statements on Monday, April 3, 2023. The forward-looking information reflects management’s current expectations based on information currently available and are subject to a number of risks and uncertainties that may cause outcomes to differ materially from those discussed in the forward-looking information. Although the Company believes that the assumptions and factors used in preparing the forward-looking information are reasonable, undue reliance should not be placed on such information and no assurance can be given that such events will occur in the disclosed timeframes or at all. Factors that could cause actual results or events to differ materially from current expectations include: (i) adverse market conditions; (ii) changes to the growth and size of the tobacco markets; (iii) changes to the regulatory landscape applicable to the Company's business; and (iv) other factors beyond the control of the Company. The Company operates in a rapidly evolving environment. New risk factors emerge from time to time, and it is impossible for the Company’s management to predict all risk factors, nor can the Company assess the impact of all factors on Company’s business or the extent to which any factor, or combination of factors, may cause actual results to differ from those contained in any forward-looking information. The forward-looking information included in this news release are made as of the date of this news release and the Company expressly disclaims any intention or obligation to update or revise any forward-looking information whether as a result of new information, future events or otherwise, except as required by applicable law.
The statements in this news release have not been evaluated by Health Canada or the U.S. Food and Drug Administration. As each individual is different, the benefits, if any, of taking the Company’s products will vary from person to person. No claims or guarantees can be made as to the effects of the Company’s products on an individual’s health and well-being. The Company’s products are not intended to diagnose, treat, cure, or prevent any disease.
This news release may contain trademarked names of third-party entities (or their respective offerings with trademarked names) typically in reference to (i) relationships had by the Company with such third-party entities as referred to in this release and/or (ii) client/vendor/service provider parties whose relationship with the Company is/are referred to in this release. All rights to such trademarks are reserved by their respective owners or licensees.
Statement Regarding Third-Party Investor Relations Firms
Disclosures relating to investor relations firms retained by TAAT® Global Alternatives Inc. can be found under the Company's profile on http://sedar.com.
FAQ
When will TAAT file its Fiscal Q1 2023 financial statements?
What was the proposed acquisition that TAAT terminated?
What are the main categories of products that TAAT is expanding into?
What is the significance of the termination of the Break Free™ acquisition for TAAT?
